OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press46510.17650/1818-8346-2021-16-1-64-72SUPPORTIVE THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИDifferences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myelomaРазличия во взаимодействии с костным микроокружением между солидными опухолями и множественной миеломой: патогенетические аспекты. Возможности и эффективность остеомодифицирующих агентов при множественной миеломеhttps://orcid.org/0000-0002-0170-5681SnegovoyA. V.СнеговойА. В.
Russian Federation

Anton Vladimirovich Snegovoy.

24 Kashirskoe Shosse, Moscow 115478.

Снеговой Антон Владимирович.

115478 Москва, Каширское шоссе, 24.

anvs2012@gmail.comhttps://orcid.org/0000-0002-4614-606XLarionovaV. B.ЛарионоваВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

https://orcid.org/0000-0002-7142-2986KononenkoI. B.КононенкоИ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaНациональный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России1404202116164721404202114042021https://oncohematology.abvpress.ru/ongm/article/view/465

Bone metastasis is one of the most common manifestations of advanced malignant process. Many tumors, especially breast, prostate and lung cancer, multiple myeloma, are characterized by a high incidence of bone damage (up to 7080 %) and clinical complications. Intense pain, hypercalcemia, spinal cord compression, pathological fractures, the need for radiation and surgical treatment (combined in the name «skeletal system related events») can occur even with single metastases. In the treatment of patients with bone metastases, a multidisciplinary approach is used; however, the basis is specific antitumor therapy and osteomodifying agents. They affect bone remodeling and microenvironment.

Метастазирование в кости является одним из наиболее частых признаков распространенного злокачественного процесса. Многие опухоли, особенно рак молочной железы, предстательной железы, легкого, множественная миелома, характеризуются высокой частотой поражения костных структур (до 70-80 %) и клиническими осложнениями. Даже при единичных метастазах могут возникать интенсивный болевой синдром, гиперкальциемия, компрессия спинного мозга, патологические переломы, потребность в лучевом и хирургическом лечении, которые объединены названием «события, связанные с костной системой». При лечении больных с метастазами в костях используется мультидисциплинарный подход, однако основой являются специфическая противоопухолевая терапия и остеомодифицирующие агенты. Они воздействуют на процессы ремоделирования костной ткани и микроокружение.

bone metastasisosteomodifying agentbisphosphonatedenosumabmultiple myelomaметастазирование в костиостеомодифицирующий агентбисфосфонатденосумабмножественная миеломаColeman R.E., Abrahamsson P.A., Hadji P. Handbook of cancer-related bone disease. BioScientifica Ltd, 2010. 221 p.Reagan M.R., Liaw L., Rosen C.J., Ghobrial I.M. Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast. Bone 2015;75:161—9. DOI: 10.1016/j.bone.2015.02.021.Wick M.R. Metastases to bone. Semin Diagn Pathol 2014;31(1):53—65. DOI: 10.1053/j.semdp.2013.12.001.Coleman R.E., Body J.J., Aapro M. et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014;25(Suppl. 3):iii124—37. DOI: 10.1093/annonc/mdu103.Neledov D.V., Shavladze N.Z. Bone metastases diagnosis: the possibilities of whole-body magnetic resonance imaging. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2009;(Suppl. 1):142—3. (In Russ.).Неледов Д.В., Шавладзе Н.З. Диагностика метастазов в кости: возможности методики магнитно-резонасной томографии всего тела. Сибирский онкологический журнал 2009;(прил. 1):142—3.Petrova A.D. Drug treatment efficacy of bone metastases in patients with breast cancer. Dis. . candidate of medical sciences. Moscow, 2014. (In Russ.).Петрова А.Д. Оценка эффективности лекарственного лечения метастазов в костях у больных раком молочной железы. Дис. ... канд. мед. наук. М., 2014.Seibel M.J. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005;2(10):504—17. DOI: 10.1038/ncponc0320.Vinholes J., Coleman R., Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996;22(4):289—331. DOI: 10.1016/s0305-7372(96)90021-3.Pecherstorfer M., Zimmer-Roth I., Schilling T. et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. Clin Endocrinol Metab 1995;80(1):97—103. DOI: 10.1210/jcem.80.1.7829646.Jung K., Lein M., Stephan C. et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111(5):783—91. DOI: 10.1002/ijc.20314.Bone metabolism markers. Available at: www.biochemmack.ru. (In Russ.).Маркеры метаболизма костной ткани. Доступно по: www.biochemmack.ru.Lacroix M., Marie P.J., Body J.J. Protein production by osteoblasts: modulation by breast cancer cell-derived factors. Breast Cancer Res Treat 2000;61(1):59—67. DOI: 10.1023/a:1006408916224.Tahtela R., Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996;16(4B):2289—93.Pecoraro V., Roli L., Germagnoli L., Banfi G. The prognostic role of bone turnover markers in multiple myeloma patients: the impact of their assay. A systematic review and meta-analysis. Crit Rev Oncol Hematol 2015;96(1):54—66. DOI: 10.1016/j.critrevonc.2015.05.001.Woitge H.W., Pecherstorfer M., Li Y. et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14(5):792—801. DOI: 10.1359/jbmr.1999.14.5.792.Lipton A., Demers L., Curley E. et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34(13):2021—6. DOI: 10.1016/s0959-8049(98)00277-9.Souberbielle J.C., Cormier C., Kindermans C. Bone markers in clinical practice. Curr Opin Rheumatol 1999;11(4):312—9. DOI: 10.1097/00002281-199907000-00016.Vinholes J.J., Purohit O.P., Abbey M.E. et al. Relationships between biochemical and symptomatic response in a doubleblind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8(12):1243-50. DOI: 10.1023/a:1008238422151.Miura H., Yamamoto I., Takada M. et al. Diagnostic validity of bone metabolic markers for bone metastasis. Endocr J 1997;44(5):751-7. DOI: 10.1507/endocrj.44.751.Hou M.F., Tsai L.Y., Tsai S.M. et al. Biochemical markers for assessment of bone metastases in patients with breast cancer. Kaohsiung J Med Sci 1999;15(8):452-60.Petrova A.D., Stenina M.B., Manzyuk L.V. et al. Time course of changes in bone resorption markers during pamidronate therapy in breast cancer patients with bone metastases. Opukholi zhenskoy reproduktivnoy systemy = Tumors of Female Reproductive System 2013;(1-2):23-7. (In Russ.). DOI: 10.17650/1994-4098-2013-0-1-2-23-27.Петрова А.Д., Стенина М.Б., Манзюк Л.В. и др. Динамика маркеров костной резорбции на фоне терапии памидронатом больных раком молочной железы с костными метастазами. Опухоли женской репродуктивной системы 2013;(1-2):23-7. OI: 10.17650/1994-4098-2013-0-1-2-23-27.Chesnut C.H. III. Sources of biological bone marker variation. In: Bone markers: Biochemical and clinical perspectives. Eds.: R. Eastell, M. Baumann, N.R. Hoyle. London: Martin Dunitz, 2001. Pp. 119-121.Seibel M.J., Lang M., Geilenkeuser W.J. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47(8):1443-50.Koizumi M., Yonese J., Fukui I., Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001;7(4):348-51. DOI: 10.1046/j.1464-410x.2001.00105.x.Leeming D.J., Koizumi M., Qvist P. et al. Serum N-terminal propeptide of collagen type i is associated with the number of bone metastases in breast and prostate cancer and correlates to other bone related markers. Biomark Cancer 2011:3:15-23. DOI: 10.4137/BIC.S6484.Aktas B., Kasmir-Bauer S., Lehmann N. et al. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. Oncol Rep 2013;30(1):441-7. DOI: 10.3892/or.2013.2409.Wang Z., Lu Y., Qiao D. et al. Diagnostic and prognostic validity of serum bone turnover markers in bone metastatic non-small cell lung cancer patients. J Bone Oncol 2015;4(3):85-91. DOI: 10.1016/j.jbo.2015.09.003.Coleman R.E. The Clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002;94(10): 2521-3. DOI: 10.1002/cncr.10522.Vinholes J., Coleman R., Lacombe D. et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 1999;80(1-2):221-8. DOI: 10.1038/sj.bjc.6690506.Lipton A., Cook R., Saad F. et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113(1):193-201. DOI: 10.1002/cncr.23529.Raje N., Terpos E., Willenbacher W. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018;19(3):370-81. DOI: 10.1016/S1470-2045(18)30072-X.Anderson K., Ismaila N., Flynn P.J. et al. Role of bonemodifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2018;36(8):812-8. DOI: 10.1200/JCO.2017.76.6402.Aparicio A., Gardner A., Tu Y. et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12(2):220-9. DOI: 10.1038/sj.leu.2400892.Shipman C.M., Rogers M.J., Apperley J.F. et al. Bisphosphonates induce apoptosis in human myeloma cells: a novel antitumour activity. Br J Haematol 1997;98(3):665-72. DOI: 10.1046/j.1365-2141.1997.2713086.x.Dhodapkar M.V., Singh J., Mehta J. et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol 1998;103(2):530-2. DOI: 10.1046/j.1365-2141.1998.00976.x.Aviles A., Nambo M.J., Neri N. et al. Antitumor effects of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24(2):227-30. DOI: 10.1007/BF02698044.Aviles A., Neri N., Huerta-Guzman J., Nambo M.J. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol 2013;20(1):e13-20. DOI: 10.3747/co.20.1055.Morgan G.J., Davies F.E., Gregory W.M. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376(9757):1989-99. DOI: 10.1016/S0140-6736(10)62051-X.Mhaskar R., Kumar A., Miladinovic B., Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev 2017;12(12):CD003188. DOI: 10.1002/14651858.CD003188.pub4.